LITTLE FALLS, N.J. (MedPage Today) -- The risk of tuberculosis is higher for patients receiving anti-tumor necrosis factor (anti-TNF) monoclonal antibody therapy than for those receiving soluble TNF receptor therapy for any indication, French researchers found.
Post new comment